CO14 Patient-Reported Outcomes (PROS) With Ramucirumab Versus Placebo in Chinese Patients With Hepatocellular Carcinoma (HCC) and Elevated Alpha-Fetoprotein From the Randomized Phase 3 Reach-2 Study
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.095
https://www.valueinhealthjournal.com/article/S1098-3015(22)02299-9/fulltext
Title :
CO14 Patient-Reported Outcomes (PROS) With Ramucirumab Versus Placebo in Chinese Patients With Hepatocellular Carcinoma (HCC) and Elevated Alpha-Fetoprotein From the Randomized Phase 3 Reach-2 Study
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02299-9&doi=10.1016/j.jval.2022.09.095
First page :
Section Title :
Open access? :
No
Section Order :
10460